Sorafenib and
lenvatinib showed efficacy for patients with radioactive
iodine (RAI)-refractory differentiated
thyroid cancer (DTC) in pivotal phase 3 clinical trials. Although the efficacy of
lenvatinib in patients who received previous treatment with multi-target
kinase inhibitors (m-TKIs), including
sorafenib, was reported, the efficacy of
sorafenib in patients who previously received
lenvatinib remains unknown. A 75-year-old woman diagnosed as RAI-refractory poorly differentiated
carcinoma with multiple lung
metastases and started treatment with
lenvatinib. She continued to receive
lenvatinib but with repeated dose interruptions and reductions due to continuous
proteinuria. Because of severe and persistent
proteinuria as well as newly developed renal impairment,
lenvatinib was suspended after two years of treatment. After the 7-month
suspension, her
proteinuria and renal impairment were partially improved, but her lung
metastases progressed. Because she was unable to tolerate previous treatment with
lenvatinib,
sorafenib was started. At 7 months of treatment with
sorafenib, her lung
metastases shrank and she could continue
sorafenib without exacerbation of
proteinuria or renal impairment. This case may suggest that
sorafenib does not exacerbate the
proteinuria or renal impairment induced by
lenvatinib, and may be an effective treatment option for RAI-refractory DTC patients who are unable to tolerate
lenvatinib.